NAMS Stock — NewAmsterdam Pharma Company N.V.: Cash, EV, Pipeline

What they do

We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy.

Source: 10-K FY2025 via SEC EDGAR

Share price

$18.90

Market cap

$2,266.7M

Cash

$643.1M

Enterprise value

$1,623.6M

Balance sheet

Cash	$643.1M
Debt	$0.0M
Net cash	$643.1M
Enterprise value	$1,623.6M
Basic shares	119.9M shares
Fully diluted shares	149.0M shares
Fully diluted market cap	$2,815.2M
Cash per share	$5.36
Quarterly burn	$39.2M
Cash runway	16.2 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

125.7M

Pre-funded warrants

0.0M

Options

19.9M

RSUs

1.0M

Warrants

2.4M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

149.0M

Cap table as of 2026-08-03.

Price history

Loading NAMS daily closes…

Loading price history…

Next catalyst

Obicetrapib 10mg · Now - Nov 24, 2026 Now · Phase 2 · Antioxidant Absorption

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	Obicetrapib 10mg	Phase 2	Antioxidant Absorption	—
GUIDEDDec 1-31 in 24d	Obicetrapib Phase 3 RUBENS study in type 2 diabetes and metabolic syndrome	Phase 3	type 2 diabetes and metabolic syndrome	Year-end 2026
Dec 13, 2026 - Jan 24, 2027 in 5 wks	Obicetrapib	Phase 3	Atherosclerotic Cardiovascular Disease	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
Dec 13, 2026 - Jan 24, 2027 in 5 wks	obicetrapib 10 mg	Phase 2	Dyslipidemias	—
Dec 13, 2027 - Jan 24, 2028 in 13 mo	obicetrapib 10 mg	Phase 3	Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
Apr 12 - May 24 in 17 mo	obicetrapib 10 mg	Phase 3	Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
Oct 13 - Nov 24 in 24 mo	Obicetrapib 10 mg	Phase 2	Preclinical Alzheimer's Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Obicetrapib

Phase 3 · Active Modality: oral CETP inhibitor

Target CETP

Partnerships Menarini (exclusive commercialization rights in the majority of European countries)

Indications

LDL-C lowering in ASCVD and HeFH (Phase 3)
primary hypercholesterolemia (HeFH and non-familial/mixed dyslipidemia) (Phase 3)

Catalysts

— Q4 2026
— Q1 2027
— end of 2027
— 2H 2026

Status note BROADWAY, BROOKLYN and TANDEM Phase 3 completed; CHMP positive opinion July 2026; potential Germany/UK launch Q4 2026. One row covers monotherapy and ezetimibe fixed-dose combination.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Obicetrapib
Lead indication	Atherosclerotic Cardiovascular Disease
Lead phase	Phase 3
Active trials	7
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05202509	Phase 3	Active, not recruiting	Sponsor	NAMS	—	Atherosclerotic Cardiovascular Disease	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
NCT06305559	Phase 3	Active, not recruiting	Sponsor	NAMS	—	Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
NCT07219602	Phase 3	Active, not recruiting	Sponsor	NAMS	—	Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)	Year-end 2026 Q1 2027 Est. Feb 14, 2027 · quarter midpoint
NCT06496243	Phase 2	Recruiting	Sponsor	NAMS	—	Dyslipidemias	—
NCT07794670	Phase 2	Not yet recruiting	Sponsor	NAMS	—	Preclinical Alzheimer's Disease	—
NCT06982508	Phase 2	Recruiting	Sponsor	NAMS	—	Antioxidant Absorption	—
NCT05972278	Phase 1	Active, not recruiting	Sponsor	NAMS	—	Lipid Metabolism	—
NCT07478887	Not disclosed	Recruiting	Collaborator	Johns Hopkins University	AMGN	Cardiovascular Risk; LDL-C; Lipids	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 8 active trials for NewAmsterdam Pharma on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	18,589,235	+1,145,128	13.58%	2026-08-14
RA Capital Management	9,550,191	no change	2.81%	2026-08-14
Deerfield Management	4,357,576	no change	1.53%	2026-08-14
Cormorant Asset Management	500,000	-450,000	0.87%	2026-08-14
ADAR1 Capital Management	118,623	no change	0.19%	2026-08-14
Logos Global Management	0	-600,000	0.00%	2026-08-14
DAFNA Capital	0	-20,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

NAMS — NewAmsterdam Pharma Company N.V. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

NAMS — NewAmsterdam Pharma Company N.V.